• BioNexus Gene Lab signed a definitive agreement with Ruanyun Edai Technology for an exclusive Malaysian healthcare licence to CogniAI.
• Plans to build document-intelligence applications for Malaysia’s public healthcare digitalisation programme, spanning 150 hospitals and more than 2,000 clinics.
• Consideration set at 410,000 common shares for a stated US$3.5 million, with no cash payment; closing remains pending.
• BioNexus to issue 150,000 additional common shares in exchange for 500,000 Ruanyun Edai ordinary shares at closing.
• Ruanyun Edai to receive a 10% royalty on defined technology receipts actually collected; no minimum royalty or annual platform fee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9841339) on October 07, 2026, and is solely responsible for the information contained therein.